Compound guide
From cellular signaling to what those pathways mean in everyday language.
Overview
APX-3 is Apex’s catalog name for a single-peptide research compound that engages GLP-1, GIP, and glucagon signaling—an approach sometimes informally described as “GLP-3.”
It combines three metabolic signals in one molecule: one helps reduce appetite, one strengthens the response to nutrients and glucose, and one increases the use of stored energy.
Inside the body
These receptors, enzymes, and signaling networks form the primary steps connecting this compound with changes inside cells and tissues.
In pancreatic beta cells, GLP-1 receptor signaling raises cyclic AMP and activates PKA and EPAC pathways that amplify glucose-dependent insulin release. In the brain and digestive system, the pathway promotes satiety and slows gastric emptying.
GIP receptors are found in pancreatic beta cells and other metabolic tissues. Their Gs–cyclic-AMP signaling also amplifies insulin release when glucose is elevated. Cell studies indicate that APX-3 has especially strong activity at this receptor.
Glucagon receptors are concentrated in the liver. Their cyclic-AMP and PKA signaling can increase hepatic glucose output, but it can also increase fatty-acid oxidation, reduce lipid synthesis, and raise energy expenditure. The paired incretin activity is intended to counterbalance the glucose-raising side of glucagon signaling.
See the complete pathway
Follow each APX-3 signal from its molecular target to its plain-English meaning.
Activates PKA and EPAC signaling inside the cell.
Supports satiety, slower gastric emptying and glucose-dependent insulin release.
Less hunger and a stronger glucose response after eating.
Strengthens nutrient-responsive signaling inside the cell.
Amplifies insulin release when glucose is elevated.
Helps the body manage incoming glucose and nutrients.
Sends a fuel-mobilization signal through the cell.
Influences fuel availability and energy expenditure.
Adds an energy-demand signal to the appetite pathways.
Three signals working together
In plain English
Reduced food intake can support weight loss, while stronger glucose-dependent insulin signaling can lower post-meal glucose and HbA1c.
This pathway likely complements GLP-1 signaling to improve glucose control and may contribute to the overall weight response.
Greater energy use and hepatic fat oxidation may help explain the additional weight and liver-fat reductions observed in studies.
GLP-1 places a brake on food intake, GIP strengthens glucose-dependent nutrient signaling, and glucagon adds an energy-use signal. The three receptors work as a coordinated metabolic network rather than as three unrelated switches.
Read the evidence
Continue exploring
More compounds organized within the metabolic signaling area.
AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to study lipid metabolism separately from full-length growth-hormone signaling.
Open compound guide ↗
5-Amino-1MQ is a small-molecule inhibitor used to study nicotinamide N-methyltransferase (NNMT), an enzyme involved in nicotinamide and methyl-donor metabolism.
Open compound guide ↗One important note
APX-3 has randomized human data for obesity, type 2 diabetes, and liver-fat outcomes. The reported effects and adverse events belong to the specific formulations, doses, populations, and study conditions cited below.
This guide explains cellular mechanisms and published outcomes in everyday language. It is educational information, not medical advice or instructions for personal use. Products offered on this site are intended exclusively for laboratory research and are not for human or veterinary use.
